Radiopharm Theranostics logo

Radiopharm Theranostics Share Price (NASDAQ: RADX)

$5.7

Last updated on

Check the interactive Radiopharm Theranostics Stock chart to analyse performance

Radiopharm Theranostics Ltd Key Stats

Check Radiopharm Theranostics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$5.7
Open
$5.8
Market Capitalization
$33.7M
Today's Volume
$10.7K
Revenue TTM
$330.6K
EBITDA
$-33.0M
Earnings Per Share (EPS)
$-11.97
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-112.21%

Stock Returns calculator for Radiopharm Theranostics Stock including INR - Dollar returns

The Radiopharm Theranostics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Radiopharm Theranostics investment value today

Current value as on today

₹37,542

Returns

₹62,458

(-62.46%)

Returns from Radiopharm Theranostics Stock

₹67,742 (-67.74%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Radiopharm Theranostics Stock

100%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Radiopharm Theranostics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Radiopharm Theranostics Stock

Rating
Trend

Radiopharm Theranostics Share Price Target

What analysts predicted

Upside of 140.45%

Target:

$13.71

Current:

$5.70

Radiopharm Theranostics share price target is $13.71, a slight Upside of 140.45% compared to current price of $5.70 as per analysts' prediction.

Radiopharm Theranostics Stock Insights

  • Price Movement

    In the last 1 month, RADX stock has moved up by 22.9%

Radiopharm Theranostics Technicals Summary

Sell

Neutral

Buy

Radiopharm Theranostics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Radiopharm Theranostics Ltd Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Radiopharm Theranostics Ltd logo
21.28%
3.64%
-67.74%
-67.74%
-67.74%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Radiopharm Theranostics Ltd

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Organization
Radiopharm Theranostics
Employees
0
CEO
Mr. Riccardo Canevari
Industry
Miscellaneous

Key Management of Radiopharm Theranostics Ltd

NameTitle
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
Founder & Executive Chairman
Mr. Riccardo Canevari
MD, CEO & Director
Mr. Phillip Hains
CFO, Joint Company Secretary & Director
Dr. Dimitris Voliotis M.D.
Chief Medical Officer
Mr. Hitesh Goel
Head of Project Management
Mr. Nathan Jong C.A.
Joint Company Secretary

Important FAQs about investing in RADX Stock from India :

What is Radiopharm Theranostics share price today?

Radiopharm Theranostics share price today is $5.70 as on at the close of the market. Radiopharm Theranostics share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Radiopharm Theranostics share?

Radiopharm Theranostics share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Radiopharm Theranostics stock price today i.e. is closed at $5.70, lower by 88.78% versus the 52 week high.

How to invest in Radiopharm Theranostics Stock (RADX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Radiopharm Theranostics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Radiopharm Theranostics Shares that will get you 0.2632 shares as per Radiopharm Theranostics share price of $5.70 per share as on August 30, 2025 at 1:27 am IST.

What is the minimum amount required to buy Radiopharm Theranostics Stock (RADX) from India?

Indian investors can start investing in Radiopharm Theranostics (RADX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Radiopharm Theranostics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Radiopharm Theranostics share’s latest price of $5.70 as on August 30, 2025 at 1:27 am IST, you will get 1.7544 shares of Radiopharm Theranostics. Learn more about fractional shares .

What are the returns that Radiopharm Theranostics has given to Indian investors in the last 5 years?

Radiopharm Theranostics stock has given -67.74% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?